Brief: Evaxion Announces Encouraging Initial Phase 2 Clinical Data On Its Personalized Cancer Vaccine EVX-01

Evaxion A/S

31/10/2023 15:16

Oct 31 (Reuters) - Evaxion Biotech A/S  EVAX.O :
    * EVAXION ANNOUNCES ENCOURAGING INITIAL PHASE 2 CLINICAL
DATA ON
ITS PERSONALIZED CANCER VACCINE EVX-01
    * EVAXION BIOTECH A/S - INITIAL EVX-01 PHASE 2 DATA CONFIRMS
STRONG PHASE 1 RESULTS
    * EVAXION BIOTECH A/S - PHASE 2 DATA CONFIRMS EVAXION'S
AI-IMMUNOLOGY PLATFORM'S ABILITY TO IDENTIFY THERAPEUTICALLY
RELEVANT CANCER VACCINE TARGETS
    * EVAXION BIOTECH A/S: UPON EVX-01 TREATMENT, A PRONOUNCED
AND
ONGOING TUMOR REDUCTION WAS OBSERVED IN A PATIENT WITH
PROGRESSIVE DISEASE
    * EVAXION BIOTECH A/S - PHASE 2 DATA CONFIRM FAVORABLE
SAFETY
PROFILE OF EVX-01 OBSERVED IN PHASE 1 TRIAL

Source text for Eikon:  ID:nGNX2C6LcV 
Further company coverage:  EVAX.O 

 ((Reuters.Briefs@thomsonreuters.com;))